Kinaxo and Daiichi Sankyo in cancer drug development collaboration
1 Oct 2010
German biotechnology company Kinaxo Biotechnologies GmbH has
signed a long-term partnership agreement with Japanese company Daiichi
Sankyo Company Limited to develop cancer drugs.
Under the agreement, Daiichi Sankyo will employ Kinaxo’s technology
platform to support the development of Daiichi Sankyo’s targeted
cancer drugs. This will involve Kinaxo applying its proprietary
chemical proteomics technologies Cellular Target Profiling and
KinAffinity as well as its phosphoproteomics technology PhosphoScout
within various research programs pursued at Daiichi Sankyo.
Financial details of the agreement were not disclosed.
Cellular Target Profiling and KinAffinity use a combination of
proprietary chemical proteomics and quantitative mass spectrometry
technologies to identify a small molecule’s native cellular targets
from biological samples.
PhosphoScout is a global, quantitative phosphoproteomics service
tailored to dissect cellular signal transduction pathways and their
response to drug treatment. PhosphoScout is applicable to both small
molecules and antibodies.
Axel Ullrich, Director at the Max Planck Institute for
Biochemistry in Martinsried and Kinaxo Board member commented: “To
promote innovation in cancer therapy we need to better understand
how targeted drugs interfere with de-regulated signaling in human
malignancies. To this end, Kinaxo has established a unique
technology platform that allows comprehensive analysis of cancer
signal transduction processes and their response to drug treatment.
I am convinced that these innovative technologies will significantly
contribute to the development of tomorrow’s cancer therapeutics.”
Andreas Jenne, Kinaxo’s CEO added: “We are excited and pleased to
partner with Daiichi Sankyo to support their endeavour in developing
novel medicines for cancer patients.”
Earlier this week Daiichi Sankyo announced that it will launch
its Inavir dry powder inhaler in Japan on 19 October for treatment
of flu and that it had been listed in the Dow Jones Sustainability
Index Asia Pacific. The index tracks the financial performance of
the leading sustainability-driven companies worldwide, evaluating
them thorough analysis of corporate economic, environmental and